Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
84.49
+3.82 (4.74%)
At close: Feb 6, 2026, 4:00 PM EST
84.46
-0.03 (-0.04%)
After-hours: Feb 6, 2026, 7:33 PM EST
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Protagonist Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $99.2, which forecasts a 17.41% increase in the stock price over the next year. The lowest target is $73 and the highest is $118.
Price Target: $99.2 (+17.41%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $95 → $118 | Strong Buy | Maintains | $95 → $118 | +39.66% | Feb 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $117 | Strong Buy | Maintains | $80 → $117 | +38.48% | Jan 30, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $88 → $110 | Strong Buy | Maintains | $88 → $110 | +30.19% | Jan 5, 2026 |
| Barclays | Barclays | Buy Maintains $88 → $108 | Buy | Maintains | $88 → $108 | +27.83% | Dec 17, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $98 → $115 | Strong Buy | Maintains | $98 → $115 | +36.11% | Dec 8, 2025 |
Financial Forecast
Revenue This Year
51.86M
from 434.43M
Decreased by -88.06%
Revenue Next Year
264.16M
from 51.86M
Increased by 409.41%
EPS This Year
-1.96
from 4.23
EPS Next Year
-0.14
from -1.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 99.4M | 551.3M | ||||
| Avg | 51.9M | 264.2M | ||||
| Low | 37.8M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -77.1% | 963.0% | ||||
| Avg | -88.1% | 409.4% | ||||
| Low | -91.3% | -62.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.32 | 5.29 | ||||
| Avg | -1.96 | -0.14 | ||||
| Low | -2.28 | -2.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.